These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27528717)

  • 1. Is Underutilization of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer Contributing to Inferior Survival?
    Molina AM; Hu J; Nanus DM
    J Clin Oncol; 2016 Sep; 34(27):3235-6. PubMed ID: 27528717
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? No, cytoreductive nephrectomy should no longer be routinely performed.
    Kim HL
    Curr Opin Urol; 2020 Sep; 30(5):743-745. PubMed ID: 32732627
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Chery LJ; Karam JA; Wood CG
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):696-703. PubMed ID: 27673288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive nephrectomy in metastatic renal cancer - less is more.
    Bex A; Haanen J
    Nat Rev Clin Oncol; 2018 Oct; 15(10):595-596. PubMed ID: 29967447
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be considered.
    Meza L; Chehrazi-Raffle A; Pal SK
    Curr Opin Urol; 2020 Sep; 30(5):740-742. PubMed ID: 32732626
    [No Abstract]   [Full Text] [Related]  

  • 6. [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
    Nosov AK; Novik AV; Vorobiev AV; Samartseva EE; Reva SA; Baldueva IA; Lushina PA
    Vopr Onkol; 2015; 61(3):494-8. PubMed ID: 26242167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive Nephrectomy for Synchronous Metastatic Renal Cell Carcinoma-Are There Any Favorable Risk Patients?
    Patel HD; Clark JI; Flanigan RC
    J Urol; 2021 Jul; 206(1):4-6. PubMed ID: 33560871
    [No Abstract]   [Full Text] [Related]  

  • 8. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
    Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
    Int J Clin Oncol; 2018 Jun; 23(3):553-558. PubMed ID: 29332206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib and Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
    Bajic P; Flanigan RC; Joyce CJ; Clark JI
    J Urol; 2019 Mar; 201(3):453-454. PubMed ID: 30266335
    [No Abstract]   [Full Text] [Related]  

  • 10. Metastatic papillary renal cell carcinoma regression after cytoreductive nephrectomy.
    Williams T; Rodriguez R; Murray K; Kovaleski A; Madan R; Van Veldhuizen P
    Urology; 2015 Feb; 85(2):283-7. PubMed ID: 25623665
    [No Abstract]   [Full Text] [Related]  

  • 11. Has the Age of Cytoreductive Nephrectomy Come to an End?: Commentary on: Sunitinib Alone or After Nephrectomy in Metastatic Renal-Cell Carcinoma.
    Kesch C; Black PC
    Urology; 2018 Nov; 121():1-2. PubMed ID: 30077538
    [No Abstract]   [Full Text] [Related]  

  • 12. Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer: Not All That It's Cut Out to Be.
    Lara PN; Evans CP
    JAMA Oncol; 2019 Feb; 5(2):171-172. PubMed ID: 30543365
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytoreductive nephrectomy is dead, long live cytoreductive nephrectomy.
    Capitanio U; Larcher A; Montorsi F
    BJU Int; 2019 Jul; 124(1):6-7. PubMed ID: 30656818
    [No Abstract]   [Full Text] [Related]  

  • 14. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
    You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
    Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endovascular Extraction of Caval Tumor Thrombus to Facilitate Minimally Invasive Cytoreductive Nephrectomy for Metastatic Kidney Cancer.
    Rogers C; Barod R; Schwartz S; Menon M
    Eur Urol; 2015 Jul; 68(1):167-8. PubMed ID: 25843640
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy.
    Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Chi YB; Shou JZ; Zhou AP; Li CL; Ma JH; Wang JW; Sun Y
    Chin Med J (Engl); 2016 Mar; 129(5):530-5. PubMed ID: 26904986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016.
    Bex A; Ljungberg B; van Poppel H; Powles T;
    Eur Urol; 2016 Dec; 70(6):901-905. PubMed ID: 27445002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cytoreductive nephrectomy for metastatic renal cell carcinoma - obsolete?].
    Grimm MO
    Urologe A; 2019 Jan; 58(1):51-52. PubMed ID: 30515551
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial: The evolving role of cytoreductive nephrectomy.
    Singla N; Hakimi AA; Margulis V
    Curr Opin Urol; 2019 Sep; 29(5):505-506. PubMed ID: 31246591
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End.
    Massari F; Di Nunno V; Santoni M; Gatto L; Mollica V; Porta C
    Eur Urol Oncol; 2019 Sep; 2(5):603-604. PubMed ID: 31411982
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.